Cat. No.: HY-N3312

Matairesinol

고객리뷰

Based on 1 Customer Validation

Matairesinol is an orally active bioactive compound with anti-inflammatory, antioxidant and anticancer activities. Matairesinol inhibits the phosphorylation of MAPK, JNK and NF-κB, downregulates RANKL-induced NFATc1 expression and activity, and suppresses the activation of the PI3K/AKT/FOXO1 pathway. Matairesinol can be used in research related to sepsis-mediated brain injury, osteoporosis, heart failure, atopic dermatitis and cancer.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

Purity: 98.78%
CAS No.: 580-72-3
화학식: C₂₀H₂₂O₆
분자량:358.39

보관:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Matairesinol Chemical Structure

CAS No.: 580-72-3

사이즈

가격

재고

수량

Amount: USD 0.00

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- 제품 설명
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
용액&용해도
- In Vitro
순도&문서
References
Help & FAQs
Classifications
Bioz

Biological Activity

제품 설명

All p38 MAPK Isoforms :

All JNK Isoforms :

All NF-κB Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	23.8 μM Compound: 10	Anticancer activity against human A549 cells by SRB assay Anticancer activity against human A549 cells by SRB assay	[PMID: 21420296]
BV-2	IC₅₀	94.53 μM Compound: 10	Antiinflammatory activity in mouse BV2 cells assessed as inhibition of lipopolysaccharide induced NO production Antiinflammatory activity in mouse BV2 cells assessed as inhibition of lipopolysaccharide induced NO production	[PMID: 21420296]
H9	EC₅₀	2 μM Compound: 1	Antiviral activity against HIV1 in human H9 cells assessed as inhibition of viral replication Antiviral activity against HIV1 in human H9 cells assessed as inhibition of viral replication	[PMID: 11473435]
H9	IC₅₀	21.9 μM Compound: 1	Cytotoxicity against human H9 cells Cytotoxicity against human H9 cells	[PMID: 11473435]
HeLa	EC₅₀	>100 μM Compound: 2	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by WST-8 assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by WST-8 assay	[PMID: 28754364]
HeLa	CC₅₀	>50 μM Compound: 9	Cytotoxicity against human HeLa cells assessed as growth inhibition after 2 days by SRB assay Cytotoxicity against human HeLa cells assessed as growth inhibition after 2 days by SRB assay	[PMID: 30676026]
HepG2	IC₅₀	15.1 μg/mL Compound: 8	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell viability by MTT assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell viability by MTT assay	[PMID: 32223924]
HL-60	EC₅₀	74 μM Compound: 2	Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 48 hrs by WST-8 assay Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 48 hrs by WST-8 assay	[PMID: 28754364]
Neutrophil	IC₅₀	4.3 μg/mL Compound: 19	Anti-inflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced superoxide anion generation by measuring superoxide dismutase SOD-inhibitable ferricytochrome c reduction incubated for 5 mins before fMLP/CB stimulation for 3 mins Anti-inflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced superoxide anion generation by measuring superoxide dismutase SOD-inhibitable ferricytochrome c reduction incubated for 5 mins before fMLP/CB stimulation for 3 mins	[PMID: 28218000]
Neutrophil	IC₅₀	7.3 μg/mL Compound: 19	Anti-inflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release pre-incubated for 5 mins before fMLP/CB stimulation using MeO-Suc-Ala-Ala-Pro-Val-pnitroanilide as substrate Anti-inflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release pre-incubated for 5 mins before fMLP/CB stimulation using MeO-Suc-Ala-Ala-Pro-Val-pnitroanilide as substrate	[PMID: 28218000]
Neutrophil	IC₅₀	2.7 μM Compound: 8	Anti-inflammatory activity against human neutrophils assessed as inhibition of fMLF/CB-induced superoxide anion generation preincubated for 5 mins followed by fMLF addition after priming with CB for 3 mins and measured after 10 mins by spectrophotometric Anti-inflammatory activity against human neutrophils assessed as inhibition of fMLF/CB-induced superoxide anion generation preincubated for 5 mins followed by fMLF addition after priming with CB for 3 mins and measured after 10 mins by spectrophotometric	[PMID: 32223924]
Neutrophil	IC₅₀	6.6 μM Compound: 8	Anti-inflammatory activity against human neutrophils assessed as inhibition of fMLF/CB-induced elastase release preincubated for 5 mins followed by fMLF addition after priming with CB for 3 mins and measured after 10 mins by spectrophotometric analysis Anti-inflammatory activity against human neutrophils assessed as inhibition of fMLF/CB-induced elastase release preincubated for 5 mins followed by fMLF addition after priming with CB for 3 mins and measured after 10 mins by spectrophotometric analysis	[PMID: 32223924]
RAW264.7	IC₅₀	0.005 mM Compound: 9	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs	[PMID: 18986199]
RAW264.7	IC₅₀	0.005 μM/mL Compound: 9	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs	[PMID: 18986199]
SK-MEL-2	IC₅₀	>30 μM Compound: 10	Anticancer activity against human SK-MEL-2 cells by SRB assay Anticancer activity against human SK-MEL-2 cells by SRB assay	[PMID: 21420296]
SK-OV-3	IC₅₀	>30 μM Compound: 10	Anticancer activity against human SKOV3 cells by SRB assay Anticancer activity against human SKOV3 cells by SRB assay	[PMID: 21420296]
XF498	IC₅₀	23.65 μM Compound: 10	Anticancer activity against human XF498 cells by SRB assay Anticancer activity against human XF498 cells by SRB assay	[PMID: 21420296]

In Vitro

Matairesinol (1-80 μM; 48 h) exhibits minimal toxicity to NSC-34 and HT22 neuronal cells at concentrations up to 40 μM, with significant cytotoxicity only at 80 μM after 48 h of treatment^[1].
Matairesinol (5-20 μM; 48 h) reverses the anti-proliferative and pro-apoptotic effects of LPS on NSC-34 and HT22 neuronal cells, with effects detectable at 24, 48, and 72 h post-treatment^[1].
Matairesinol (5-20 μM; 48 h) attenuates LPS-mediated oxidative stress and inflammation in BV2 microglia, while modulating the expression of Nrf2/HO-1 and inhibiting MAPK/JNK/NF-κB pathway activation^[1].
Matairesinol (0.3-30 μM; 4 days) dose-dependently inhibits RANKL-induced differentiation of mouse bone marrow-derived macrophages into osteoclasts, with significant inhibition observed at concentrations ≥10 μM for osteoclast formation and ≥1 μM for TRAP activity^[2].
Matairesinol (0.3-30 μM; 3 days) does not reduce the viability of mouse bone marrow-derived macrophages^[2].
Matairesinol (10 μM; 1-3 days) suppresses RANKL-induced expression of NFATc1 and downstream osteoclastogenesis-associated genes (TRAP, OSCAR, v-ATPasev0d2) in mouse bone marrow-derived macrophages over 1-3 days of treatment^[2].
Matairesinol (10 μM; 4 days, following 8 h retroviral infection) has its inhibitory effect on RANKL-induced osteoclast differentiation reversed by ectopic overexpression of constitutively active NFATc1 in mouse bone marrow-derived macrophages, confirming NFATc1 as a key mediator of its anti-osteoclastogenic activity^[2].
Matairesinol (10 μM; 1 h pre-incubation, followed by RANKL stimulation for 5, 15, 30 min) suppresses RANKL-induced activation of p38 and ERK (but not JNK) MAPK signaling pathways in mouse bone marrow-derived macrophages^[2].
Matairesinol (0-100 μM) at 50 μM maintains viability in Ang II-stimulated NRVMs, while 100 μM reduces viability under basal conditions^[3].
Matairesinol (50 μM) attenuates Ang II-induced hypertrophy in NRVMs by reducing cell size and suppressing hypertrophy-related gene expression^[3].
Matairesinol (50 μM) inhibits Ang II-induced activation of NRCFs by reducing fibrotic marker expression and suppressing the TGF-β/Smad3 pathway^[3].
Matairesinol (50 μM) ameliorates oxidative stress in Ang II-stimulated NRVMs by reducing ROS levels^[3].
Matairesinol (10-500 μM; 72 h) inhibits proliferation of HUVECs (IC₅₀ 75 μM) more potently than HeLa cells (IC₅₀ 200 μM)^[5].
Matairesinol (10-100 μM; 48 h, 72 h) does not induce cytotoxicity in HUVECs at concentrations up to 50 μM when treated for 72 h, or at 100 μM when treated for 48 h^[5].
Matairesinol (10-20 μM; 3-16 h) dose-dependently inhibits VEGF-induced capillary tube formation in serum-starved HUVECs^[5].
Matairesinol (20-80 μM) dose-dependently reduces PCNA protein expression in PANC-1 and MIA PaCa-2 pancreatic cancer cells, with 80 μM causing a 30% and 33% reduction in the respective cell lines^[6].
Matairesinol (80 μM; 3 days) inhibits 3D spheroid formation in PANC-1 and MIA PaCa-2 pancreatic cancer cells, reducing spheroid area by 78% and 61% in the respective cell lines^[6].
Matairesinol (20-80 μM; 48 h) dose-dependently induces late apoptosis in PANC-1 and MIA PaCa-2 pancreatic cancer cells, with 80 μM increasing late apoptosis by 196% and 261% in the respective cell lines over 48 h^[6].
Matairesinol (20-80 μM; 1 h) dose-dependently increases intracellular ROS production in PANC-1 and MIA PaCa-2 pancreatic cancer cells, with 80 μM increasing ROS by 447% and 548% in the respective cell lines after 1 h^[6].
Matairesinol (20-80 μM; 48 h) dose-dependently increases cytosolic calcium levels in PANC-1 and MIA PaCa-2 pancreatic cancer cells, with 80 μM increasing levels by 280% and 551% in the respective cell lines over 48 h^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay^[1]

Cell Line:

NSC-34, HT22
Concentration:

1, 2, 40, 80 μM
Incubation Time:

48 h
Result:

Showed no significant cytotoxicity at 1, 2, and 40 μM compared to the control group.
Significantly hindered cell viability at 80 μM compared to the control group.

Cell Proliferation Assay^[5]

Cell Line:

human umbilical vein endothelial cells (HUVECs), HeLa cells
Concentration:

10-500 μM
Incubation Time:

72 h
Result:

Inhibited HUVEC proliferation with an IC₅₀ of 75 μM.
Inhibited HeLa cell proliferation with an IC₅₀ of 200 μM.

Cell Invasion Assay^[5]

Cell Line:

HUVECs (VEGF-stimulated, serum-starved)
Concentration:

10-20 μM
Incubation Time:

18 h
Result:

Dose-dependently inhibited VEGF-induced HUVEC invasiveness without cytotoxic effects.

Cell Proliferation Assay^[6]

Cell Line:

PANC-1, MIA PaCa-2 human pancreatic ductal adenocarcinoma cells
Concentration:

5-100 μM; 80 μM (optimal dose)
Incubation Time:

48 h
Result:

Inhibited cell proliferation by 48% in PANC-1 cells and 50% in MIA PaCa-2 cells (p < 0.001 for both cell lines).

Apoptosis Analysis^[6]

Cell Line:

PANC-1, MIA PaCa-2 cells
Concentration:

20-80 μM
Incubation Time:

48 h
Result:

Increased relative late apoptosis by 196% in PANC-1 cells and 261% in MIA PaCa-2 cells, with late apoptosis increasing in a dose-dependent manner.

Cell Migration Assay^[6]

Cell Line:

PANC-1, MIA PaCa-2 cells
Concentration:

80 μM
Incubation Time:

24 h
Result:

Reduced the number of migrated cells by 79% in PANC-1 cells and 86% in MIA PaCa-2 cells.

Cell Proliferation Assay^[6]

Cell Line:

PANC-1, MIA PaCa-2 cells
Concentration:

80 μM (in combination with 20 μM 5-FU)
Incubation Time:

48 h
Result:

Reduced cell proliferation from 73% to 34% in PANC-1 cells and from 74% to 30% in MIA PaCa-2 cells compared to 5-FU alone.

Apoptosis Analysis^[6]

Cell Line:

MIA PaCa-2 cells
Concentration:

80 μM (in combination with 20 μM 5-FU)
Incubation Time:

48 h
Result:

Increased relative late apoptosis from 473% to 704% in MIA PaCa-2 cells compared to 5-FU alone.

In Vivo

Matairesinol (5-20 mg/kg; p.o.; single dose) concentration-dependently reduces sepsis-mediated brain injury in CLP-induced rats by exerting anti-inflammatory, antioxidant, and neuroprotective effects via up-regulating AMPK and inhibiting MAPK and NF-κB pathways^[1].
Matairesinol (100 mg·kg⁻¹·d⁻¹; intraperitoneal injection; daily; 3 weeks) improves cardiac function, reduces cardiac hypertrophy and remodeling, inhibits cardiomyocyte apoptosis, and mitigates oxidative stress in TAC-induced mice by upregulating Prdx1 and inhibiting the PI3K/AKT/FOXO1 pathway, with these effects blunted by Prdx1 knockdown^[3].
Matairesinol (topical; daily; 11 days) effectively suppresses DfE-induced atopic dermatitis in NC/Nga mice by reducing ear swelling, serum IgE levels, inflammatory cell infiltration, mast cell numbers, and normalizing IL-4 and IFN-γ mRNA expression^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

unspecified (6-8 weeks old)^[1]
Dosage:

5 mg/kg; 10 mg/kg; 20 mg/kg
Administration:

p.o.; single dose
Result:

Reduced serum concentrations of S100β, GFAP, and NSE relative to CLP-only rats, with significant effects at 10 and 20 mg/kg for all three markers.
Reduced brain tissue expression of Caspase-3 relative to CLP-only rats, with significant effects at 10 and 20 mg/kg.
Reduced serum and brain tissue levels of pro-inflammatory cytokines TNF-α, IL-1β, IL-6, IFN-γ, IL-8, and MCP1 relative to CLP-only rats, with significant effects at 10 and 20 mg/kg for all cytokines.
Reduced the number of Iba-1-positive activated microglia in brain tissue relative to CLP-only rats, with significant effects at 10 and 20 mg/kg.

Animal Model:

C57BL/6 (male, 8-10 weeks old, 23-28 g, transverse aortic constriction surgery-induced)^[3]
Dosage:

100 mg·kg^-1·d^-1
Administration:

intraperitoneal injection; daily; 3 weeks
Result:

Restored left ventricular ejection fraction (EF) and fractional shortening (FS), and reduced left ventricular end-diastolic dimension (LVEDd) in TAC-induced mice.
Reduced heart weight-to-body weight ratio (HW/BW) and heart weight-to-tibia length ratio (HW/TL).
Suppressed mRNA expression of hypertrophy markers ANP, BNP, and β-MHC.
Normalized protein expression of apoptosis-related markers (reduced Bax and Caspase3, increased Bcl-2).
Reduced myocardial reactive oxygen species (ROS) levels.
Restored protein expression of antioxidant markers HO-1 and SOD2.

Chemical Information

CAS No. 580-72-3
Appearance Solid
분자량 358.39
화학식 C₂₀H₂₂O₆
Color White to yellow
SMILES

O=C1OC[C@H](CC2=CC=C(O)C(OC)=C2)[C@H]1CC3=CC=C(O)C(OC)=C3
Structure Classification
- Phenylpropanoids
- Lignans
- Phenols
- Polyphenols
Initial Source
- Plants
- other families
선적

Room temperature in continental US; may vary elsewhere.
보관

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

용액&용해도

In Vitro:

DMSO : 200 mg/mL (558.05 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.7903 mL

13.9513 mL

27.9026 mL

5 mM

0.5581 mL

2.7903 mL

5.5805 mL

10 mM

0.2790 mL

1.3951 mL

2.7903 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

몰농도 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

농도 희석 계산기

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

순도&문서

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (297 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Wu Q, et al. Matairesinol exerts anti-inflammatory and antioxidant effects in sepsis-mediated brain injury by repressing the MAPK and NF-κB pathways through up-regulating AMPK. Aging (Albany NY). 2021;13(20):23780-23795. [Content Brief]

[2]. Choi SW, et al. Anti-osteoclastogenic activity of matairesinol via suppression of p38/ERK-NFATc1 signaling axis. BMC Complement Altern Med. 2014;14:35. Published 2014 Jan 21. [Content Brief]

[3]. Zhang T, et al. Matairesinol blunts adverse cardiac remodeling and heart failure induced by pressure overload by regulating Prdx1 and PI3K/AKT/FOXO1 signaling. Phytomedicine. 2024;135:156054. [Content Brief]

[4]. Sung YY, et al. Forsythia suspensa fruit extracts and the constituent matairesinol confer anti-allergic effects in an allergic dermatitis mouse model. J Ethnopharmacol. 2016;187:49-56. [Content Brief]

[5]. Lee B, et al. Matairesinol inhibits angiogenesis via suppression of mitochondrial reactive oxygen species. Biochem Biophys Res Commun. 2012;421(1):76-80. [Content Brief]

[6]. Lee W, et al. Matairesinol Induces Mitochondrial Dysfunction and Exerts Synergistic Anticancer Effects with 5-Fluorouracil in Pancreatic Cancer Cells. Mar Drugs. 2022;20(8):473. Published 2022 Jul 25. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.7903 mL	13.9513 mL	27.9026 mL	69.7564 mL
	5 mM	0.5581 mL	2.7903 mL	5.5805 mL	13.9513 mL
	10 mM	0.2790 mL	1.3951 mL	2.7903 mL	6.9756 mL
	15 mM	0.1860 mL	0.9301 mL	1.8602 mL	4.6504 mL
	20 mM	0.1395 mL	0.6976 mL	1.3951 mL	3.4878 mL
	25 mM	0.1116 mL	0.5581 mL	1.1161 mL	2.7903 mL
	30 mM	0.0930 mL	0.4650 mL	0.9301 mL	2.3252 mL
	40 mM	0.0698 mL	0.3488 mL	0.6976 mL	1.7439 mL
	50 mM	0.0558 mL	0.2790 mL	0.5581 mL	1.3951 mL
	60 mM	0.0465 mL	0.2325 mL	0.4650 mL	1.1626 mL
	80 mM	0.0349 mL	0.1744 mL	0.3488 mL	0.8720 mL
	100 mM	0.0279 mL	0.1395 mL	0.2790 mL	0.6976 mL

Keywords

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

상품명:
CAS No.:
Species:
Purity:
수량:

Matairesinol

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Phenols Library

Pyroptosis Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Food-Sourced Compound Library

Anti-Liver Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Osteogenesis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Anti-Rheumatic Arthritis Compound Library

Mass Spectrometry Human Metabolite Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Flavors and Fragrances Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

All p38 MAPK Isoforms

All JNK Isoforms

All NF-κB Isoforms

Biological Activity

Chemical Information

용액&용해도

순도&문서

References

Help & FAQs

Complete Stock Solution Preparation Table

Matairesinol Related Classifications

HY-N3312 Related Classifications